CFHR4-Specific Antibodies for Geographic Atrophy Complement Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration, particularly the advanced form known as Geographic Atrophy (GA), are ineffective, and there is a need for new therapeutic approaches targeting the complement activation system to address this condition.
Innovation Solution
Development of antibodies directed against Complement Factor H Related 4 (CFHR4) peptides, specifically designed with defined complementarity determining regions (CDRs) to inhibit complement activation, thereby reducing complement component 3 (C3) convertase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complement regulators are used to treat AMD, then complement activation is inhibited, but treatment effectiveness has not been achieved
Solution Approach 1:
The patent changes the target parameter from general complement regulation to specific CFHR4 inhibition. By designing antibodies that specifically bind to CFHR4 (complement factor H-related protein 4), the invention modifies the molecular target parameter to achieve effective treatment. This specific targeting approach addresses the limitation of non-effective general complement regulators while maintaining control over complement activation.
2Loss of information
If genetic risk variants in complement system genes are considered, then pathogenesis understanding is improved, but treatment complexity increases
Solution Approach 1:
The patent extracts the specific CFHR4 component from the complex complement system. By isolating and targeting only CFHR4 with specific antibodies, the invention simplifies the treatment approach while maintaining effectiveness. This extraction principle allows the therapy to focus on a single critical component rather than addressing the entire complex complement system, thereby reducing treatment complexity despite the sophisticated understanding of pathogenesis.
3Measurement precision
If CFHR4 antibodies are designed with specific CDRs, then binding affinity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by defining specific complementarity determining regions (CDRs) within the antibody structure. The heavy chain CDRs (HCDR1, HCDR2, HCDR3) and light chain CDRs (LCDR1, LCDR2, LCDR3) are identified as distinct functional segments. This segmentation allows for precise engineering of binding affinity in specific regions while maintaining standardized production protocols for the rest of the antibody molecule, thus balancing manufacturing feasibility with high binding affinity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-CFHR4 antibodies effectively bind to CFHR4, reducing complement activation and potentially slowing the progression of GA, offering a novel therapeutic approach for AMD.
Implementation Method 1
antibodies directed against Complement Factor H Related 4 (CFHR4) peptides, or antigen-binding fragments thereof
Data Source
AI summary
The present disclosure relates to the treatment and/or prevention of age-related macular degeneration (AMD), including the advanced form of dry AMD referred to as Geographic Atrophy (GA). In particular, the present disclosure provides novel therapeutic antibodies that target components of the alternative pathway of the complement activation system, including complement factor H-related (CFHR) 4.